• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    High Tide Announces Details of Consolidation to Meet NASDAQ Listing Requirements

    5/12/21 6:00:00 AM ET
    $APHA
    $ACB
    Specialty Chemicals
    Consumer Durables
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $APHA alert in real time by email
    • 15:1 share consolidation to begin trading on or about May 14, 2021
    • NASDAQ Capital Market listing expected in May 2021 under ticker symbol HITI

    CALGARY, AB, May 12, 2021 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (TSXV:HITI) (OTCQB:HITIF) (FRA: 2LY), a retail-focused cannabis corporation enhanced by the manufacturing and distribution of consumption accessories, is pleased to announce that it will be consolidating all of its issued and outstanding common shares ("Common Shares") on the basis of one (1) post-consolidation Common Share for each fifteen (15) pre-consolidation Common Shares (the "Share Consolidation"). The Share Consolidation represents another major step towards the listing of the Common Shares on The Nasdaq Stock Market LLC ("Nasdaq") by meeting the minimum share price requirement set by Nasdaq.

    High Tide Inc. - May 12, 2021 (CNW Group/High Tide Inc.)

    "Today's news represents a significant milestone towards High Tide becoming the first major cannabis retailer anywhere in the world to be listed on Nasdaq, making our shares more accessible to a larger audience of both retail and institutional investors, and increasing our appeal to potential M&A targets," said Raj Grover, President and Chief Executive Officer of High Tide. "The announced share consolidation, coupled with other recent progress in our application, gives us confidence that we remain on course to meet the listing standards and begin trading on Nasdaq by the end of this month," added Mr. Grover.

    The listing of High Tide's Common Shares on Nasdaq remains subject to the approval of Nasdaq and the satisfaction of all applicable listing and regulatory requirements, including the effectiveness and clearing comments of the Form 40-F. Following receipt of all required approvals, the Company will issue a press release announcing its first trading date on Nasdaq.

    Share Consolidation Details

    The Company's board of directors approved the Share Consolidation and it is expected that the Common Shares will commence trading on a post-Share Consolidation basis on the TSX Venture Exchange (the "TSXV") on or about Friday May 14, 2021.

    The Share Consolidation was approved by holders of Common Shares at the Company's annual and special meeting held on July 24, 2019. The Share Consolidation is subject to acceptance by the TSXV.

    Assuming the Share Consolidation is completed, the existing 690,834,719 Common Shares will be reduced to approximately 46,055,653 Common Shares, subject to adjustments for rounding purposes. No fractional shares will be issued. Any fractional interest in Common Shares that is less than 0.5 of a Common Share resulting from the Share Consolidation will be rounded down to the nearest whole Common Share and any fractional interest in Common Shares that is 0.5 or greater of a Common Share will be rounded up to the nearest whole Common Share.

    There are currently 35,193,728 Common Share purchase warrants originally issued by Meta Growth ("Meta Warrants") listed for trading on the TSXV, each exercisable at $0.29 per Meta Warrant for 0.824 Common Share. Following the Share Consolidation, the number of listed Meta Warrants outstanding will not be altered; however, the exercise terms will be adjusted in accordance with the terms of the warrant indenture dated February 6, 2020, as supplemented on November 16, 2020, such that fifteen Warrants will be exercisable for 0.824 post-Share Consolidation Common Share following the payment of an adjusted exercise price of $4.35.

    There are currently 23,958,332 Common Share purchase warrants originally issued as a part of the 2021 bought deal ("HITI Warrants") listed for trading on the TSXV, each exercisable at $0.58 per HITI Warrant for one Common Share. Following the Share Consolidation, the number of listed HITI Warrants outstanding will not be altered; however, the exercise terms will be adjusted in accordance with the terms of the warrant indenture dated February 22, 2021, such that fifteen HITI Warrants will be exercisable for one post-Share Consolidation Common Share following the payment of an adjusted exercise price of $8.70.

    There are currently $900,000 principal amount of convertible debentures originally issued by Meta Growth ("Convertible Debentures") listed for trading on the TSXV, convertible at $0.22 per Common Share ("Conversion Price"). Following the Share Consolidation, the number of listed Convertible Debentures outstanding will not be altered; however, the conversion terms will be adjusted in accordance with the terms of the debenture indenture dated November 23, 2018, as supplemented on November 16, 2020, such that the Conversion Price will be adjusted to $3.30 per post-Share Consolidation Common Share.

    Upon completion of the Share Consolidation, a letter of transmittal will be sent by mail to registered shareholders advising that the Share Consolidation has taken effect. The letter of transmittal will contain instructions on how registered shareholders can exchange their share certificates or Direct Registration System ("DRS") statements evidencing their pre-consolidation Common Shares for new share certificates or new DRS statements representing the number of post-consolidation Common Shares to which they are entitled.

    Beneficial shareholders holding their Common Shares through an intermediary may be subject to different procedures for obtaining their post-consolidation Common Shares. If you have questions in this regard, you are encouraged to contact your intermediary.

    The Company does not intend to change its name or seek a new stock trading symbol in connection with the Share Consolidation.

    The Company's new CUSIP number for the post-consolidation Common Shares is 42981E401 and the new ISIN number is CA42981E4013. There are no changes to the CUSIP number or ISIN number for the Meta Warrants, HITI Warrants or Convertible Debentures.

    About High Tide Inc.

    High Tide is a retail-focused cannabis company enhanced by the manufacturing and distribution of consumption accessories. The Company is the most profitable Canadian retailer of recreational cannabis as measured by Adjusted EBIDTA,1 with 85 current locations spanning Ontario, Alberta, Manitoba and Saskatchewan. High Tide's retail segment features the Canna Cabana, KushBar, Meta Cannabis Co., Meta Cannabis Supply Co. and NewLeaf Cannabis banners, with additional locations under development across the country. High Tide has been serving consumers for over a decade through its numerous consumption accessory businesses including e-commerce platforms Grasscity.com, Smokecartel.com and CBDcity.com, and its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide's strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value. Key industry investors in High Tide include Aphria Inc. (TSX:APHA) (NYSE:APHA) and Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB).

    _____________________

    1 Adjusted EBITDA is a non-IFRS financial measure.

    Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

    Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements regarding High Tide and its business include, but are not limited to, statements with respect to: the potential listing of High Tide's Shares on Nasdaq, the timing thereof, receipt of regulatory approval for, and the Form 40-F Registration Statement with the SEC. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting High Tide, including risks relating to the listing of High Tide's securities in the United States, a shutdown of the United States government, the Nasdaq listing not providing High Tide with broadened access to international investors or enhance High Tide's liquidity, the Company not expanding globally, which could result in the Company not having a diversified business platform for growth, the Company not being well positioned to pursue additional opportunities for growth, or such opportunities no longer being available to High Tide, risks associated with the geographic markets in which High Tide operates, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the cannabis industry and the regulation thereof, the failure to comply with applicable laws, the failure to obtain regulatory approvals, economic factors, market conditions, the equity and debt markets generally, risks associated with growth and competition, general economic and stock market conditions, risks and uncertainties detailed from time to time in High Tide's filings with the SEC and Canadian Securities Administrators, the COVID-19 pandemic nationally and globally and the response of governments to the COVID-19 pandemic in respect of the operation of retail stores and other risks and many other factors beyond the control of High Tide.  Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. High Tide disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/high-tide-announces-details-of-consolidation-to-meet-nasdaq-listing-requirements-301289365.html

    SOURCE High Tide Inc.

    Get the next $APHA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APHA
    $ACB

    CompanyDatePrice TargetRatingAnalyst
    Aurora Cannabis Inc.
    $ACB
    12/11/2024Buy
    TD Cowen
    Aurora Cannabis Inc.
    $ACB
    2/9/2024Hold → Buy
    Canaccord Genuity
    Aurora Cannabis Inc.
    $ACB
    9/21/2022Sell → Hold
    Canaccord Genuity
    Aurora Cannabis Inc.
    $ACB
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    Aurora Cannabis Inc.
    $ACB
    6/6/2022Sell → Hold
    Stifel
    Aurora Cannabis Inc.
    $ACB
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    Aurora Cannabis Inc.
    $ACB
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    Aurora Cannabis Inc.
    $ACB
    10/5/2021$8.30 → $9.50Neutral
    Cantor Fitzgerald
    More analyst ratings

    $APHA
    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

      VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. "Glen's leadership at Aurora C

      5/15/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB

      PALM BEACH, Fla., May 8, 2025 /PRNewswire/ -- Exec Edge announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Research is a highly specialized platform focused on US and global equities, with an emphasis on fundamental analysis. Our first round of initiation reports includes Fold Holdings, Inc (NASDAQ:FLD), Climb Bio Inc. (NASDAQ:CLYM), Rex American Resources Corp. (NYSE:REX), The ONE Group Hospitality, Inc. (NASDAQ:STKS) and Aurora Cannabis Inc. (NASDAQ:ACB). Our reports dive deep into

      5/8/25 5:40:00 PM ET
      $ACB
      $CLYM
      $FLD
      $REX
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Finance: Consumer Services
    • Aurora Cannabis Announces the Completion of a Multimillion Dollar Investment and Renaming of B.C. Manufacturing Facility

      NASDAQ | TSX: ACB Company's Long-Standing Investment in Operational Excellence Continues with Industry Leading Upgrades and Renaming the Facility to Aurora Alpine EDMONTON, AB, April 30, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces the completion of a multi-year investment of $3 million in improvements to its manufacturing facility in Pemberton, British Columbia. These upgrades are a combination of Aurora's proprietary high-performing genetics and state-of-the-art engineering design which have resulted in optimal cultivation conditions, expanded output, and superior product quality. The site has been r

      4/30/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $APHA
    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/23 11:28:04 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Aurora Cannabis Inc.

      SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

      6/1/22 10:14:29 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/22 3:54:29 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $APHA
    $ACB
    SEC Filings

    See more
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      3/20/25 9:27:09 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SUPPL filed by Aurora Cannabis Inc.

      SUPPL - AURORA CANNABIS INC (0001683541) (Filer)

      2/14/25 4:36:44 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form F-X filed by Aurora Cannabis Inc.

      F-X - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/25 4:34:39 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $APHA
    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Aurora Cannabis

      TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

      12/11/24 10:35:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

      2/9/24 6:09:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold

      9/21/22 9:02:55 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $APHA
    $ACB
    Leadership Updates

    Live Leadership Updates

    See more
    • Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

      VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. "Glen's leadership at Aurora C

      5/15/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora CEO Miguel Martin takes on additional role as Executive Chairman of Board of Directors

      NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv

      9/20/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Announces Results of 2024 Annual General and Special Meeting

      NASDAQ | TSX: ACB EDMONTON, AB, Aug. 12, 2024 /PRNewswire/ -  Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 14,855,306, representing 27.23% of Aurora's issued and outstanding common shares as of the record date. All of

      8/12/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $APHA
    $ACB
    Financials

    Live finance-specific insights

    See more
    • Aurora Cannabis Announces Fiscal 2025 Third Quarter Results

      NASDAQ | TSX: ACB Reports Total Net Revenue1 of $88.2 Million, up 37% YoY, Including Record Net Revenue1 of $68.1 Million in Global Medical Cannabis, up 51% YoYGenerates Record Net Income of $31.2 Million, up 282% YoY, and Record Adjusted EBITDA1 of $23.1 Million, up 316% YoYAchieves Target of Positive Free Cash Flow1 in Q3, Generating $27.4 Million of Free Cash Flow1Maintains Strong Balance Sheet with $180 Million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, Feb. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third qu

      2/5/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis to Host Third Quarter 2025 Investor Conference Call

      NASDAQ | TSX: ACB EDMONTON, AB, Jan. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its third quarter 2025 on Wednesday, February 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the third quarter 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, February 5, 2025 TIME: 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time WEBCAST: Click Here Miguel Martin, Executive Chairman and Chief Executive Officer,

      1/22/25 5:02:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Announces Fiscal 2025 Second Quarter Results

      NASDAQ | TSX: ACB Record Adjusted EBITDA1 of $10.1 Million, a YoY increase of 210%Quarterly Net Revenue1 up 29% YoY to $81.1 Million, with 41% growth in Global Medical CannabisRe-Affirms Target of Positive Free Cash Flow1 in the Quarter Ending December 31, 2024Maintains Strong Balance Sheet with ~$152 Million of Cash and a Debt-Free Cannabis Business2EDMONTON, AB, Nov. 6, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter fiscal 2025.

      11/6/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care